SVB Leerink Comments on Viking Therapeutics, Inc.’s Q2 2021 Earnings (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at SVB Leerink dropped their Q2 2021 earnings per share (EPS) estimates for Viking Therapeutics in a research note issued on Wednesday, April 28th. SVB Leerink analyst T. Smith now anticipates that the biotechnology company will earn ($0.21) per share for the quarter, down from their previous forecast of ($0.18). SVB Leerink has a “Buy” rating and a $18.00 price target on the stock. SVB Leerink also issued estimates for Viking Therapeutics’ Q3 2021 earnings at ($0.23) EPS, Q4 2021 earnings at ($0.24) EPS, FY2021 earnings at ($0.87) EPS, FY2022 earnings at ($1.23) EPS, FY2023 earnings at ($1.72) EPS, FY2024 earnings at ($1.84) EPS and FY2025 earnings at ($0.45) EPS.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 price objective on shares of Viking Therapeutics in a research note on Friday, January 22nd. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $16.89.

NASDAQ:VKTX opened at $5.90 on Monday. The stock’s 50-day moving average is $6.14 and its 200-day moving average is $6.52. Viking Therapeutics has a 1-year low of $5.26 and a 1-year high of $10.09. The stock has a market cap of $460.79 million, a P/E ratio of -12.04 and a beta of 2.02.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, April 28th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01).

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its position in Viking Therapeutics by 10.8% during the third quarter. JPMorgan Chase & Co. now owns 24,442 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 2,390 shares during the last quarter. Morgan Stanley grew its position in shares of Viking Therapeutics by 102.3% during the 3rd quarter. Morgan Stanley now owns 342,724 shares of the biotechnology company’s stock worth $1,994,000 after buying an additional 173,320 shares during the period. Brinker Capital Investments LLC bought a new stake in shares of Viking Therapeutics in the 3rd quarter valued at $186,000. Pacer Advisors Inc. increased its stake in shares of Viking Therapeutics by 45.0% in the 4th quarter. Pacer Advisors Inc. now owns 8,372 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 2,597 shares in the last quarter. Finally, Exane Derivatives boosted its stake in Viking Therapeutics by 14.3% during the fourth quarter. Exane Derivatives now owns 51,284 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 6,407 shares in the last quarter. 54.13% of the stock is owned by institutional investors and hedge funds.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Recommended Story: Stochastic Momentum Index (SMI)

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.